Galectin-3: What This Test Actually Measures

Galectin-3 is a blood test that measures a protein released by activated immune cells and fibroblasts as tissue scars down. In cardiology it is used almost exclusively as a prognostic marker in people already diagnosed with heart failure, not as a screening or diagnostic test. This draft is pending qualified medical review before publication; the numeric cutoffs and specific study statistics below are presented with the level of certainty the available material supports, and several precise figures from the original source material could not be independently verified and are flagged accordingly.

The core answer

Galectin-3 (encoded by the LGALS3 gene, sometimes called Mac-2 in older literature) is a biomarker of fibrosis, not a diagnostic test for any single disease. In heart failure it adds prognostic information beyond natriuretic peptides such as BNP or NT-proBNP, and it carries a Class IIb ("may be considered") recommendation in the 2013/2017 ACC/AHA/HFSA heart failure guideline for additive risk stratification, not for diagnosis or for guiding a specific treatment change. No randomized trial has shown that adjusting therapy based on a galectin-3 result improves survival compared with standard care, so a high or low result should inform risk conversation rather than trigger a specific intervention on its own.

What the protein is and what it is not

Galectin-3 belongs to a family of proteins (lectins) that bind sugar structures on cell surfaces. Macrophages and fibroblasts release it when tissue is under sustained mechanical or metabolic stress, and it appears to help drive collagen deposition, the physical process of scarring. This is a mechanistic finding from cell and animal studies plus correlational human data; it is not the same as saying galectin-3 causes heart failure in a given patient.

It helps to place galectin-3 next to two markers readers may already know:

• Troponin rises with active myocardial cell death (an acute injury signal).
• BNP / NT-proBNP rises with stretch on the ventricular wall (a hemodynamic pressure/volume signal that changes quickly with fluid status and diuretic treatment).
• Galectin-3 rises with ongoing structural remodeling and fibrosis, a slower process that does not turn over hour to hour.

Because these three markers reflect different biology, an abnormal result in one does not substitute for the others, and a normal troponin or BNP does not rule out fibrotic remodeling captured by galectin-3.

How the test is performed

A galectin-3 test uses a standard venous blood draw (serum or EDTA plasma); fasting is not required. Laboratories run it on immunoassay platforms (ELISA or chemiluminescent immunoassay formats). An FDA-cleared assay for this marker (the BGM Galectin-3 Test) received 510(k) clearance around 2010 as an aid to assessing prognosis in chronic heart failure, alongside standard clinical evaluation, according to the original FDA clearance summary. Confirm the current clearance status and labeled indication directly against the FDA's 510(k) database before treating this as current, since device clearances and marketing arrangements can change and this draft has not re-verified the primary filing.

What counts as a normal, borderline, or high result

Validation studies in heart failure cohorts (commonly cited as PRIDE and COACH in the literature) reported a three-tier pattern: levels below roughly 17.8 ng/mL associated with lower short-term event rates, an intermediate band, and levels above roughly 25.9 ng/mL associated with meaningfully worse outcomes. These specific cut points, and the exact event rates and hazard ratios attached to them in various publications, are the kind of precise numbers that need to be checked against the original papers before they appear in a public-facing reference page; treat the cutoffs above as commonly cited in the validation literature rather than as independently confirmed by this draft.

Two structural points matter more than the exact cutoff:

• Kidney function moves the number. Galectin-3 is cleared renally, so reduced eGFR raises circulating levels independent of what is happening in the heart. A galectin-3 result in a patient with eGFR below roughly 60 mL/min/1.73m² should be interpreted alongside renal function, not read as a pure cardiac fibrosis signal.
• Assay platforms are not fully interchangeable. Because different manufacturers' assays have not been fully harmonized, serial monitoring in the same patient should use the same laboratory and method over time; comparing a result from one platform to a cutoff derived on another can be misleading.

What a high result suggests, and what it does not prove

Observational studies have associated higher galectin-3 with worse outcomes in chronic heart failure, with incident atrial fibrillation, with progression of liver fibrosis in fatty liver disease, and with progression of chronic kidney disease. These associations come from cohort and case-control designs, which show correlation with outcomes rather than proof that lowering galectin-3 itself would change those outcomes. The precise effect sizes reported in individual studies (hazard ratios, odds ratios, area-under-curve values) are the type of number that should not be repeated on a public page without checking the original paper, and several of the citations attached to those numbers in earlier drafts of this material could not be confirmed to be correctly matched, so they have been removed here pending verification rather than republished with an uncertain source.

What a low result suggests

A result in the lower reference range is reassuring in the sense that it is associated with lower short-term event rates in the cohorts that established the assay's use. A very low galectin-3 has no recognized clinical syndrome in humans; animal knockout studies show altered inflammatory and infection responses in galectin-3-deficient mice, but that finding has not translated into a clinical concern for people with a low measured level. If someone has heart failure symptoms with a low galectin-3, clinicians typically look harder at non-fibrotic causes, such as valvular disease or arrhythmia-driven cardiomyopathy, or consider that fibrosis may simply not have progressed far yet.

How it fits with other cardiac biomarkers

Galectin-3 is generally used as one input among several rather than a stand-alone result. NT-proBNP tracks current hemodynamic stress and can change within days of a diuretic dose; galectin-3 changes over weeks to months and reflects the more durable structural picture. sST2 (soluble suppression of tumorigenicity 2) is another fibrosis-associated marker with the same Class IIb guideline standing as galectin-3; it responds more to acute hemodynamic swings, which is why some clinicians favor it in acute decompensated heart failure and view galectin-3 as more informative in stable, ambulatory patients. Combining multiple markers has been studied and can reclassify some patients' risk category compared with any single marker, but routine triple-marker testing outside specialized heart failure programs is not standard practice, largely on cost and guideline grounds.

Can galectin-3 be lowered, and should that be a goal?

No therapy is FDA-approved specifically to lower galectin-3, and no trial has shown that lowering the number itself improves survival. Several interventions have shown an association with lower levels as a secondary or exploratory finding:

• Modified citrus pectin, a compound that binds the carbohydrate-recognition domain of galectin-3, reduced levels in a small human trial. The trial was small, and larger confirmatory studies are lacking; anyone considering a supplement for this purpose should discuss dose and rationale with their own clinician rather than follow a number found online, since this article does not provide individualized dosing guidance.
• Weight loss, including after bariatric surgery, has correlated with drops in galectin-3 alongside other inflammatory markers in observational data.
• Mineralocorticoid receptor antagonists (spironolactone, eplerenone) reduce cardiac fibrosis markers generally, with some suggestion of a modest galectin-3 effect in secondary analyses.
• SGLT2 inhibitors have anti-fibrotic signals in cardiac tissue studies, though a reported reduction in galectin-3 in at least one large heart failure trial substudy did not reach statistical significance.
• Statins have inconsistent observational associations with lower galectin-3 and this is not a recognized indication for statin use.

Blood pressure control, glycemic control, and exercise address the upstream drivers of fibrosis (hypertension, hyperglycemia, obesity) even though direct evidence that they lower galectin-3 specifically is thin. None of this should be read as a treatment protocol; it is a summary of where research attention has gone, not a recommendation to start or stop a therapy based on a galectin-3 number.

When clinicians actually order this test

Galectin-3 is not part of routine annual bloodwork and the 2017 ACC/AHA/HFSA guideline explicitly limits its recommended use to people with an established heart failure diagnosis, not screening of asymptomatic people. Typical scenarios include a baseline measurement at the time of a new heart failure diagnosis (particularly heart failure with preserved ejection fraction, where diffuse fibrosis is a feature), serial measurement in patients with recurrent hospitalizations to gauge whether fibrotic burden is progressing, and inclusion in some transplant-center prognostic workups. Galectin-3 is also an active research marker in oncology, where it is implicated in tumor microenvironment biology, but that use remains investigational and is not a basis for cancer screening or diagnosis today.

Where the evidence is solid, where it is thin, and where it stops

Established: galectin-3 is a biologically plausible and FDA-recognized biomarker of fibrosis, it adds prognostic information in chronic heart failure beyond natriuretic peptides, and renal function materially affects the result.

Plausible but not proven: that galectin-3 tracks fibrosis burden in atrial fibrillation, liver disease, and kidney disease meaningfully enough to guide individual patient decisions in those conditions; that lowering galectin-3 with any current intervention changes hard outcomes; that a specific numeric cutoff performs identically across assay platforms and patient populations.

Not established: that galectin-3 can diagnose heart failure or any other condition on its own; that galectin-3-guided treatment intensification improves survival compared with standard guideline-directed care; that any supplement or drug produces a clinically meaningful, reproducible reduction in galectin-3 in a way tied to better outcomes.

Anyone with new or worsening shortness of breath, swelling, chest pain, or a rapid weight gain should seek urgent evaluation regardless of any galectin-3 result; this test does not substitute for that assessment.

A reader's decision framework for a galectin-3 result

Use this as a way to organize a conversation with a clinician, not as a self-diagnosis tool.

References and verification note

This draft describes findings commonly attributed to heart failure biomarker validation cohorts (referred to in the literature as PRIDE, COACH, and DEAL-HF), the 2013/2017 ACC/AHA/HFSA heart failure guideline update, and the original FDA 510(k) clearance summary for the BGM Galectin-3 Test (submission K101942). The specific PubMed identifiers, hazard ratios, and confidence intervals that appeared in the prior version of this article could not be confirmed to correctly match their cited claims during this review and have been removed or generalized rather than republished. Before this page is treated as reference-grade, an editor should pull the primary publications for the PRIDE, COACH, DEAL-HF, PREVEND, and Framingham galectin-3 analyses directly, confirm the current ACC/AHA/HFSA heart failure guideline language on galectin-3, and re-verify the FDA 510(k) clearance status and labeled indication in the FDA's public device database.